Neuropathological and immunochemical studies of brain parenchyma in acetylcholinesterase knockout mice: Implications in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 11, Issue 4, 2007, Pages 481-489

  Rice, Stephen G ^a   Nowak, Lee ^a   Duysen, Ellen G ^b   Lockridge, Oksana ^b   Lahiri, Debomoy K ^c   Reyes, Patricio F ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; CD34; Cholinergic hypothesis; Glial fibrillary acidic protein; HLA DP; Neuron specific enolase; Synaptophysin

Indexed keywords

ACETYLCHOLINESTERASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DENDRITIC CELL; ENDOTHELIUM CELL; IMMUNOCHEMISTRY; KNOCKOUT MOUSE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VASCULAR DISEASE; WILD TYPE;

EID: 34447649707     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2007-11410     Document Type: Article

References (24)

1. R.E. Becker, P. Moriearty, L. Unni and S. Vicari, in: Alzheimer's disease: from molecular biology to therapy, R. Becker and E. Giacobini, eds, Boston, Birkḧauser, 1977, pp. 257-266.
2. J.L. Cummings, Behavioral and neuropsychiatric outcomes in Alzheimer's disease, CNS Spectr 11(Suppl 18) (2005), 22-25.
3. S. Darvesh, D.A. Hopkins and C. Geula, Neurobiology of butyrylcholinesterase, Nat Rev Neurosci 4(2) (2003), 131-138.
4. S.T. DeKosky and S.W. Scheff, Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity, Ann Neurol 5 (1990), 457-464.
5. P.M. Doraiswamy, Non-cholinergic strategies for treating and preventing Alzheimer's Disease, CNS Drugs 16(12) (2002), 811-824.
6. M.F. Eskander, N.G. Nagykery, E.Y. Leung, B. Khelghati and C. Geula, Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles, Brain Research 1060 (2005), 144-152.
7. B.J. Franklin and G. Paxinos, The mouse brain in stereotaxic coordinates, Academic Press, San Diego, 2001.
8. E. Giacobini, Cholinesterases: new roles in brain function and in Alzheimer's disease, Neurochem Res 28(3-4) (2003), 515-522.
9. E. Giacobini, Cholinesterase inhibitors: new roles and therapeutic alternatives, Pharmacological Res 50 (2004), 433-440.
10. N.H. Greig, D.K. Lahiri and K. Sambamurti, Butyrylcholinesterase: an important new target in Alzheimer's disease therapy, Int Psychogeriatr 14(Suppl 1) (2002), 77-91.
11. N.H. Greig, T. Utsuki, D.K. Ingram, Y. Wang, G. Pepeu, C. Scali, Q.S. Yu, A. Brossi, J. Mamczarz, H.W. Holloway, K. Furukawa, K. Sambamurti and D.K. Lahiri, Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers β-amyloid peptide in rodents, Proc Natl Acad Sci USA 102(47) (2005), 17213-17218.
12. J. Hardy and D.J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science 297(5580) (2002), 353-356.
13. J.S. Jacobsen, C.C. Wu, J.M. Redwine, T.A. Comery et al., Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease, Proc Natl Acad Sci USA 103(13) (2006), 5161-5166.
14. D.K. Lahiri, M.R. Farlow, K. Sambamurti, N.H. Greig, E. Giacobini and L.S. Schneider, A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease, Curr Drug Targets 4(2) (2003), 97-112.
15. D.K. Lahiri, J.T. Rogers, N.H. Greig and K. Sambamurti, Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents, Curr Pharm Des 10 (2004), 3111-3119.
16. B. Li, J.A. Stribley, A. Ticu, W. Xie, L.M. Schopfer, P. Hammond, S. Brimijoin, S.H. Hinrichs and O. Lockridge, Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse, Journal of Neurochemistry 75 (2000), 1320-1331.
17. M.M. Mesulam, A. Guillozet, P. Shaw, A. Levey, E.G. Duysen and O. Lockridge, Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine, Neuroscience 110(4) (2002), 627-629.
18. M. Mesulam, in: Cholinesterases and cholinesterase inhibitors, Giacobini, ed., Martin Dunitz, London, 2000, pp. 121-136.
19. Progress report on Alzheimer's disease 2004-2005. (2006, March 6) http://www.nia.nih.gov/Alzheimers/Publications/ADProgress2004_2005/chap01.htm.
20. K.T.Y. Shaw, T. Utsuki, J. Rogers, Q.S. Yu, K. Sambamurti, A. Brossi, Y.W. Ge, D.K. Lahiri and N.H. Greig, Phenserine regulates translation of β-amyloid precursor mRNA by a putative interleukin-1 responsive element, a target for drug development, Proc Natl Acad Sci USA 98 (2001), 7605-7610.
21. D.G. Wilkinson, P.T. Francis, E. Schwam and J. Payne-Parrish, Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmalogical effects and clinical efficacy, Drugs and Aging 2(7) (2004), 453-478.
22. C.I. Wright, C. Geula and M.M. Mesulam, Neuroglia cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability, Annals of Neurology 34(3) (1993), 373-384.
23. J. Hartmann, C. Kiewert, E.G. Duysen, O. Lockridge, N.H. Greig and J. Klein, Excessive hippocampal acetylcholine levels in acetylcholinesterase- deficient mice are moderated by butyrylcholinesterase activity, Journal of Neurochemistry 100 (2007), 1421-1429.
24. D.K. Lahiri, D. Chen, B. Maloney, H.W. Holloway, Q.-S. Yu, T. Utsuki, T. Giordano, K. Sambamurti and N.H. Greig, The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice, Journal of Pharmacological & Experimental Therapeutics 320(1) (2007), 386-396.